InsiderTrades.com logo
Chris Francis net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Chris Francis Biography and Net Worth

insider of Wave Life Sciences

Since joining Wave in April 2014, Dr. Chris Francis has contributed to Wave’s private and public financings and led the formation of external research collaborations, including the ongoing collaborations with Takeda and GSK. Chris is also a co-inventor of Wave platform-related intellectual property.

Prior to Wave, Chris led strategy, business development and scientific operations for GSK’s immuno-oncology unit; licensing and contributing to the early development of multiple programs currently in clinical trials. He began his career in healthcare private equity with Two River LLC and pharmaceutical pricing reimbursement consulting with IMS Health.

Chris received undergraduate and graduate degrees in biochemistry and biophysics from the University of Melbourne, and doctoral training at the University of Cambridge.

How old is Chris Francis?

Francis is currently 46 years old. There are 3 older executives and no younger executives at Wave Life Sciences. The oldest executive at Wave Life Sciences is Dr. Chandra Vargeese Ph.D., Chief Technology Officer, who is 63 years old. Learn More on Chris Francis' age.

How do I contact Chris Francis?

The corporate mailing address for Francis and other Wave Life Sciences executives is 7 STRAITS VIEW #12-00 MARINA ONE EAST TOWER, SINGAPORE U0, 018936. Wave Life Sciences can also be reached via phone at (656) 236-3388 and via email at krausch@wavelifesci.com. Learn More on Chris Francis' contact information.

Has Chris Francis been buying or selling shares of Wave Life Sciences?

Chris Francis has not been actively trading shares of Wave Life Sciences over the course of the past ninety days. Most recently, Chris Francis sold 36,000 shares of the business's stock in a transaction on Friday, November 8th. The shares were sold at an average price of $16.00, for a transaction totalling $576,000.00. Learn More on Chris Francis' trading history.

Who are Wave Life Sciences' active insiders?

Wave Life Sciences' insider roster includes Paul Bolno (CEO), Chris Francis (insider), Christian Henry (Director), and Kyle Moran (CFO). Learn More on Wave Life Sciences' active insiders.

Are insiders buying or selling shares of Wave Life Sciences?

In the last twelve months, Wave Life Sciences insiders bought shares 1 times. They purchased a total of 2,791,930 shares worth more than $22,335,440.00. In the last twelve months, insiders at the sold shares 10 times. They sold a total of 697,211 shares worth more than $8,522,029.83. The most recent insider tranaction occured on March, 20th when Director Christian O Henry sold 10,500 shares worth more than $102,585.00. Insiders at Wave Life Sciences own 29.1% of the company. Learn More about insider trades at Wave Life Sciences.

Information on this page was last updated on 3/20/2025.

Chris Francis Insider Trading History at Wave Life Sciences

See Full Table

Chris Francis Buying and Selling Activity at Wave Life Sciences

This chart shows Chris Francis's buying and selling at Wave Life Sciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$2M$0$2MTotal Insider BuyingTotal Insider Selling

Wave Life Sciences Company Overview

Wave Life Sciences logo
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.
Read More

Today's Range

Now: $9.01
Low: $8.91
High: $10.05

50 Day Range

MA: $10.78
Low: $9.01
High: $12.24

2 Week Range

Now: $9.01
Low: $4.25
High: $16.74

Volume

1,710,902 shs

Average Volume

1,108,939 shs

Market Capitalization

$1.38 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A